MARKET

RDUS

RDUS

Radius Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.52
+0.56
+2.81%
Closed 16:21 05/11 EDT
OPEN
19.32
PREV CLOSE
19.96
HIGH
20.81
LOW
19.28
VOLUME
475.95K
TURNOVER
--
52 WEEK HIGH
26.16
52 WEEK LOW
10.15
MARKET CAP
969.42M
P/E (TTM)
-8.7219
1D
5D
1M
3M
1Y
5Y
Would Shareholders Who Purchased Radius Health's (NASDAQ:RDUS) Stock Three Years Be Happy With The Share price Today?
Simply Wall St. · 20h ago
Global Osteoporosis Drugs Market Report Analysis, Share, Revenue, Growth Rate With Forecast Overview
Comserve · 1d ago
Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag
Zacks.com · 1d ago
SVB Leerink Maintains Market Perform on Radius Health, Raises Price Target to $24
SVB Leerink analyst Geoffrey Porges maintains Radius Health (NASDAQ:RDUS) with a Market Perform and raises the price target from $23 to $24.
Benzinga · 1d ago
DJ Radius Health Price Target Raised to $24.00/Share From $23.00 by SVB Leerink
Dow Jones · 1d ago
DJ Radius Health Is Maintained at Market Perform by SVB Leerink
Dow Jones · 1d ago
--SVB Leerink Adjusts Radius Health PT to $24 From $23, Maintains Market Perform Rating
MT Newswires · 1d ago
8-K: Radius Health, Inc.
(EDGAR Online via COMTEX) -- false 0001428522 0001428522 2021-05-07 2021-05-07 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDUS. Analyze the recent business situations of Radius Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDUS stock price target is 24.43 with a high estimate of 33.00 and a low estimate of 18.00.
EPS
Institutional Holdings
Institutions: 206
Institutional Holdings: 60.96M
% Owned: 129.05%
Shares Outstanding: 47.24M
TypeInstitutionsShares
Increased
41
4.62M
New
16
349.45K
Decreased
48
2.92M
Sold Out
16
1.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.34%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Owen Hughes
President/Chief Executive Officer/Director
G. Kelly Martin
Chief Financial Officer/Chief Accounting Officer/Treasurer
James Chopas
Senior Vice President
Chhaya Shah
Other
Bruce Mitlak
Director
Sean Murphy
Director
Machelle Sanders
Director
Andrew Von Eschenbach
No Data
About RDUS
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

Webull offers kinds of Radius Health Inc stock information, including NASDAQ:RDUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDUS stock methods without spending real money on the virtual paper trading platform.